𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia—Comparison with historic experience

✍ Scribed by Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Jianqin Shan; Mary Beth Rios; Richard Champlin; Marcos de Lima; Jorge Cortes

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
291 KB
Volume
103
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib mesylate therapy improves survi
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase : Comparison with historic data
✍ Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Francis J. Giles; Mary Beth Ri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

## Abstract ## BACKGROUND The International Randomized study of Interferon‐alpha plus cytarabine (IFN‐α plus ara‐C) versus STI571 (imatinib mesylate) [IRIS trial] in patients with newly diagnosed Philadelphia chromosome (Ph)‐positive, chronic‐phase chronic myelogenous leukemia (CML) has not shown

The significance of myelosuppression dur
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
✍ Thomas B. Sneed; Hagop M. Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rio 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression ≥ Grade 3, requiring interruption of thera

Imatinib mesylate therapy reduces bone m
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia
✍ Carlos E. Bueso-Ramos; Jorge Cortes; Moshe Talpaz; Susan O'Brien; Francis Giles; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 1 views

## Abstract ## BACKGROUND Reticulin‐stained bone marrow fibrosis is associated with a poor prognosis in patients with chronic myelogenous leukemia (CML). Resolution of fibrosis with therapy may improve patient outcome. ## METHODS The effect of imatinib therapy on bone marrow fibrosis was evaluat

Persistent neutropenia in chronic myelog
Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
✍ Yu-Yan Hwang; Eric Tse; Jason C.C. So; Thomas S.K. Wan; Yok-Lam Kwong 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

A physician or a group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary.